IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v21y2020i4d10.1007_s10198-020-01159-y.html
   My bibliography  Save this article

Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients

Author

Listed:
  • Simone A. Huygens

    (University Medical Center
    Erasmus University
    Erasmus University)

  • Isaac Corro Ramos

    (Erasmus University)

  • Carlijn V. C. Bouten

    (Eindhoven University of Technology)

  • Jolanda Kluin

    (Academic Medical Centre)

  • Shih Ting Chiu

    (Providence Health and Service)

  • Gary L. Grunkemeier

    (Providence Health and Service)

  • Johanna J. M. Takkenberg

    (University Medical Center)

  • Maureen P. M. H. Rutten-van Mölken

    (Erasmus University
    Erasmus University)

Abstract

Objectives Aortic valve disease is the most frequent indication for heart valve replacement with the highest prevalence in elderly. Tissue-engineered heart valves (TEHV) are foreseen to have important advantages over currently used bioprosthetic heart valve substitutes, most importantly reducing valve degeneration with subsequent reduction of re-intervention. We performed early Health Technology Assessment of hypothetical TEHV in elderly patients (≥ 70 years) requiring surgical (SAVR) or transcatheter aortic valve implantation (TAVI) to assess the potential of TEHV and to inform future development decisions. Methods Using a patient-level simulation model, the potential cost-effectiveness of TEHV compared with bioprostheses was predicted from a societal perspective. Anticipated, but currently hypothetical improvements in performance of TEHV, divided in durability, thrombogenicity, and infection resistance, were explored in scenario analyses to estimate quality-adjusted life-year (QALY) gain, cost reduction, headroom, and budget impact. Results Durability of TEHV had the highest impact on QALY gain and costs, followed by infection resistance. Improved TEHV performance (− 50% prosthetic valve-related events) resulted in lifetime QALY gains of 0.131 and 0.043, lifetime cost reductions of €639 and €368, translating to headrooms of €3255 and €2498 per hypothetical TEHV compared to SAVR and TAVI, respectively. National savings in the first decade after implementation varied between €2.8 and €11.2 million (SAVR) and €3.2–€12.8 million (TAVI) for TEHV substitution rates of 25–100%. Conclusions Despite the relatively short life expectancy of elderly patients undergoing SAVR/TAVI, hypothetical TEHV are predicted to be cost-effective compared to bioprostheses, commercially viable and result in national cost savings when biomedical engineers succeed in realising improved durability and/or infection resistance of TEHV.

Suggested Citation

  • Simone A. Huygens & Isaac Corro Ramos & Carlijn V. C. Bouten & Jolanda Kluin & Shih Ting Chiu & Gary L. Grunkemeier & Johanna J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken, 2020. "Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 557-572, June.
    • Handle: RePEc:spr:eujhec:v:21:y:2020:i:4:d:10.1007_s10198-020-01159-y
    DOI: 10.1007/s10198-020-01159-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-020-01159-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-020-01159-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
    2. David M. Eddy & William Hollingworth & J. Jaime Caro & Joel Tsevat & Kathryn M. McDonald & John B. Wong, 2012. "Model Transparency and Validation," Medical Decision Making, , vol. 32(5), pages 733-743, September.
    3. Tim A Kanters & Clazien A M Bouwmans & Naomi van der Linden & Siok Swan Tan & Leona Hakkaart-van Roijen, 2017. "Update of the Dutch manual for costing studies in health care," PLOS ONE, Public Library of Science, vol. 12(11), pages 1-11, November.
    4. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629, Decembrie.
    5. Jonathan Karnon & James Stahl & Alan Brennan & J. Jaime Caro & Javier Mar & Jörgen Möller, 2012. "Modeling Using Discrete Event Simulation," Medical Decision Making, , vol. 32(5), pages 701-711, September.
    6. Oliver Rivero-Arias & Melissa Ouellet & Alastair Gray & Jane Wolstenholme & Peter M. Rothwell & Ramon Luengo-Fernandez, 2010. "Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome," Medical Decision Making, , vol. 30(3), pages 341-354, May.
    7. Tien-En Tan & Gary S L Peh & Benjamin L George & Howard Y Cajucom-Uy & Di Dong & Eric A Finkelstein & Jodhbir S Mehta, 2014. "A Cost-Minimization Analysis of Tissue-Engineered Constructs for Corneal Endothelial Transplantation," PLOS ONE, Public Library of Science, vol. 9(6), pages 1-9, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jesús Isaac Vázquez-Serrano & Rodrigo E. Peimbert-García & Leopoldo Eduardo Cárdenas-Barrón, 2021. "Discrete-Event Simulation Modeling in Healthcare: A Comprehensive Review," IJERPH, MDPI, vol. 18(22), pages 1-20, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Matthew R Behrend & María-Gloria Basáñez & Jonathan I D Hamley & Travis C Porco & Wilma A Stolk & Martin Walker & Sake J de Vlas & for the NTD Modelling Consortium, 2020. "Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 14(4), pages 1-17, April.
    2. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    3. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    4. Paul Tappenden & James Chilcott, 2014. "Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models," PharmacoEconomics, Springer, vol. 32(10), pages 967-979, October.
    5. Maximilian Hatz & Reiner Leidl & Nichola Yates & Björn Stollenwerk, 2014. "A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 32(4), pages 377-393, April.
    6. Manal H. El-Hamamsy & Gihan H. Elsisi & Randa Eldessouki & Mohamed M. Elmazar & Ahmed S. Taha & Basma F. Awad & Hossam Elmansy, 2016. "Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 431-440, August.
    7. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    8. Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas, 2017. "The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(1), pages 1-12, March.
    9. Magnus Zingmark & Ingeborg Nilsson & Fredrik Norström & Klas Göran Sahlén & Lars Lindholm, 2017. "Cost effectiveness of an intervention focused on reducing bathing disability," European Journal of Ageing, Springer, vol. 14(3), pages 233-241, September.
    10. Steffen Flessa & Dominik Dietz & Elisabete Weiderpass, 2016. "Health policy support under extreme uncertainty: the case of cervical cancer in Cambodia," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 183-218, November.
    11. Ben Kearns & Roberta Ara & Allan Wailoo & Andrea Manca & Monica Alava & Keith Abrams & Mike Campbell, 2013. "Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations," PharmacoEconomics, Springer, vol. 31(8), pages 643-652, August.
    12. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    13. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
    14. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    15. Thi-Phuong-Lan Nguyen & E Pamela Wright & Thanh-Trung Nguyen & C C M Schuiling-Veninga & M J Bijlsma & Thi-Bach-Yen Nguyen & M J Postma, 2016. "Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam," PLOS ONE, Public Library of Science, vol. 11(5), pages 1-17, May.
    16. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    17. David Brain & Jonathan Mitchell & James O’Beirne, 2020. "Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-13, June.
    18. Han-I. Wang & Alexandra Smith & Eline Aas & Eve Roman & Simon Crouch & Cathy Burton & Russell Patmore, 2017. "Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(2), pages 255-267, March.
    19. Carmen Selva-Sevilla & F Dámaso Fernández-Ginés & Manuel Cortiñas-Sáenz & Manuel Gerónimo-Pardo, 2021. "Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-18, September.
    20. Gerardus Frederix & Hossein Haji Ali Afzali & Erik Dasbach & Robyn Ward, 2015. "Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions," PharmacoEconomics, Springer, vol. 33(8), pages 777-781, August.

    More about this item

    Keywords

    Early health technology assessment; Patient-level simulation model; Heart valve implantation; Tissue-engineered heart valves;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:21:y:2020:i:4:d:10.1007_s10198-020-01159-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.